Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future

From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future

Published

on

From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future

In this episode of the Podcast, SynBioBeta founder and CEO, John Cumbers, speaks with Harshal Chokhawala, co-founder and CEO of ZymoChem, about how the company is reengineering the foundations of materials science using microbial fermentation. Harshal discusses his scientific journey from organic chemistry to building a carbon-conserving biotech platform capable of producing bio-based adipic acid, a key component in nylon 66. Their recent partnership with lululemon aims to bring sustainable, high-performance textiles to market.

The conversation also touches on ZymoChem’s second major innovation: a biodegradable superabsorbent polymer for use in diapers—a response to the overwhelming waste generated by the hygiene industry. Harshal explains their BAYSE platform, the technology powering these innovations, and how they’re scaling up production to meet market demand.

The discussion closes with thoughts on scaling biomanufacturing, policy support, and the broader bioeconomy opportunity in the U.S.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy

Published

on

The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but trial design was a major sticking point as the panel deliberated.

Continue Reading

Uncategorized

Replimune melanoma drug wins support of FDA panel

Published

on

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

Continue Reading

Uncategorized

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read More

Published

on

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Read More

Continue Reading
Advertisement

Trending